INCREASED MORTALITY

Even when treatment is optimized for comorbidities like T2D, mortality may still increase1

A prospective study evaluated 471 patients with nonfunctioning adrenal adenomas and 157 patients with endogenous adrenocorticotropic hormone (ACTH)-independent hypercortisolism.* Some patients with hypercortisolism received medications optimized for comorbidities, such as type 2 diabetes (T2D).1

2.6x greater risk for cardiovascular mortality in patients with hypercortisolism1

Patients with hypercortisolism who received only optimized medications (OM) for comorbidities† had a 2.6x increased risk for cardiovascular mortality compared to patients with nonfunctioning adenoma (NFA).

Cumulative Cardiovascular Survival in Patients During Follow-up1

Chart depicting a 2.6x greater cardiovascular mortality risk for patients with hypercortisolism.

Dexamethasone suppression test (DST) >1.8 μg/dL (or >50 nmol/L) plus 1 abnormal hormonal test of hypothalamic-pituitary-adrenal axis.1

†Pharmacological therapy optimized to reduce altered metabolic and cardiovascular parameters (eg, T2D and hypertension).1

2.6x greater risk for cardiovascular events in patients with hypercortisolism1

Patients with hypercortisolism who received only OM for comorbidities had a 2.6x increased risk for cardiovascular events compared to patients with nonfunctioning adenoma.

Chart depicting a 2.6x greater cardiovascular events risk for patients with hypercortisolism.
Blood drop on hand icon.

Hypercortisolism can lead to worsening T2D

VIEW RISKS
Blood drop icon.

How to screen for hypercortisolism in patients with T2D

VIEW SCREENING
Clipboard icon.

Review treatment options for hypercortisolism

VIEW THE OPTIONS

Reference

1. Petramala L, Olmati F, Concistrè A, et al. Endocrine. 2020;70(1):150-163. doi:10.1007/s12020-020-02297-2